Literature DB >> 21396512

A case-control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors.

Susanna Naggie1, Becky A Miller, Kimberly B Zuzak, Brian W Pence, Ashley J Mayo, Bradly P Nicholson, Preeta K Kutty, L Clifford McDonald, Christopher W Woods.   

Abstract

BACKGROUND: The epidemiology of community-associated Clostridium difficile infection is not well known. We performed a multicenter, case-control study to further describe community-associated C. difficile infection and assess novel risk factors.
METHODS: We conducted this study at 5 sites from October 2006 through November 2007. Community-associated C. difficile infection included individuals with diarrhea, a positive C. difficile toxin, and no recent (12 weeks) discharge from a health care facility. We selected controls from the same clinics attended by cases. We collected clinical and exposure data at the time of illness and cultured residual stool samples and performed ribotyping.
RESULTS: Of 1041 adult C. difficile infections, 162 (15.5%) met criteria for community-associated: 66 case and 114 control patients were enrolled. Case patients were relatively young (median 64 years), female (56%), and frequently required hospitalization (38%). Antimicrobials, malignancy, exposure to high-risk persons, and remote health care exposure were independently associated with community-associated C. difficile infection. In 40% of cases, we could not confirm recent antibiotic exposure. Stomach-acid suppressants were not associated with community-associated infection, and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors appeared protective. Prevalence of the hypervirulent NAP-1/027 strain was infrequent (17%).
CONCLUSIONS: Community-associated C. difficile infection resulted in a substantial health care burden. Antimicrobials are a significant risk factor for community-associated infection. However, other unique factors also may contribute, including person-to-person transmission, remote health care exposures, and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. A role for stomach-acid suppressants in community-associated C. difficile infection is not supported.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21396512     DOI: 10.1016/j.amjmed.2010.10.013

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  44 in total

Review 1.  The risks of PPI therapy.

Authors:  Paul Moayyedi; Grigorios I Leontiadis
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-02-14       Impact factor: 46.802

2.  Anti-reflux mucosectomy using a cap-assisted endoscopic mucosal resection method for refractory gastroesophageal disease: a prospective feasibility study.

Authors:  In Kyung Yoo; Weon Jin Ko; Hak Su Kim; Hee Kyung Kim; Jung Hyun Kim; Won Hee Kim; Sung Pyo Hong; Abdullah Özgür Yeniova; Joo Young Cho
Journal:  Surg Endosc       Date:  2019-05-28       Impact factor: 4.584

3.  Clostridium difficile infection in the community: are proton pump inhibitors to blame?

Authors:  Daniel E Freedberg; Julian A Abrams
Journal:  World J Gastroenterol       Date:  2013-10-28       Impact factor: 5.742

4.  Clostridium difficile infection in older adults.

Authors:  Robin Lp Jump
Journal:  Aging health       Date:  2013-08-01

5.  Epidemiology and outcomes of community-acquired Clostridium difficile infections in Medicare beneficiaries.

Authors:  Courtney E Collins; M Didem Ayturk; Julie M Flahive; Timothy A Emhoff; Frederick A Anderson; Heena P Santry
Journal:  J Am Coll Surg       Date:  2014-02-28       Impact factor: 6.113

6.  Statin use and the risk of Clostridium difficile in academic medical centres.

Authors:  Christine Anne Motzkus-Feagans; Amy Pakyz; Ronald Polk; Giovanni Gambassi; Kate L Lapane
Journal:  Gut       Date:  2012-03-22       Impact factor: 23.059

7.  Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection.

Authors:  Kevin A Brown; Nagham Khanafer; Nick Daneman; David N Fisman
Journal:  Antimicrob Agents Chemother       Date:  2013-03-11       Impact factor: 5.191

Review 8.  Hospital Infection Control: Clostridioides difficile.

Authors:  Nicholas A Turner; Deverick J Anderson
Journal:  Clin Colon Rectal Surg       Date:  2020-02-25

9.  Commercially available probiotic drinks containing Lactobacillus casei DN-114001 reduce antibiotic-associated diarrhea.

Authors:  Christoph G Dietrich; Tanja Kottmann; Manuela Alavi
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

Review 10.  Clostridium difficile virulence factors: Insights into an anaerobic spore-forming pathogen.

Authors:  Milena M Awad; Priscilla A Johanesen; Glen P Carter; Edward Rose; Dena Lyras
Journal:  Gut Microbes       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.